Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors

• US 20050267124A1
• Filed: 05/12/2005
• Published: 12/01/2005
• Est. Priority Date: 05/14/2004
• Status: Abandoned Application

• Current Assignee: Solvay Pharmaceuticals GmbH (Abbvie Incorporated)
• Original Assignee: Solvay Pharmaceuticals GmbH (Abbvie Incorporated)
• Inventors: Weske, Michael, Ziegler, Dieter, Witte, Klaus, Straub, Matthias, Hoeltje, Dagmar
• Application Number:
  US11/127,163
• Publication Number:
  US 20050267124A1
• Time in Patent Office: Days
• US Class Current: 514/252.160
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/5513 1,4-Benzodiazepines, e.g. diazepam or clozapine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A combination therapy for the inhibition and/or treatment of sexual dysfunction and/or cardiovascular diseases in humans and other mammals, by administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system, and at least one inhibitor of phosphodiesterase 5.

Claims

1. A pharmaceutical composition comprising in combination a pharmacologically effective quantity of each of

a) at least one NEP-inhibitor,

b) at least one inhibitor of the endogenous endothelin producing system, and

c) at least one PDE V inhibitor.

2. A pharmaceutical composition according to claim 1, further comprising at least one pharmaceutically acceptable auxiliary or carrier.

3. A pharmaceutical composition according to claim 1, wherein said composition is in orally administrable form.

4. A pharmaceutical composition according to claim 3, wherein said orally administrable form is selected from the group consisting of tablets, coated tablets, capsules, syrups, elixirs, suspensions, and combinations thereof.

5. A pharmaceutical composition according to claim 1, wherein the PDE V inhibitor is present in a unit single dosage form physically segregated from other active agents.

6. A pharmaceutical composition according to claim 1, wherein the inhibitor of the endogenous endothelin producing system is selected from the group consisting of inhibitors of endothelin converting enzyme, inhibitors of human soluble endopeptidase, and dually acting compounds capable of inhibiting endothelin converting enzyme and human soluble endopeptidase.

7. A pharmaceutical composition according to claim 1, wherein the neutral endopeptidase inhibitor (a) and the inhibitor of the endogenous endothelin producing system (b) are present together in the form of a single, dually acting compound which inhibits both neutral endopeptidase and the endogenous endothelin producing system.

8. A pharmaceutical composition according to claim 7, wherein said dually acting compound inhibits both neutral endopeptidase and human soluble endopeptidase.

9. A pharmaceutical composition according to claim 7, wherein said dually acting compound which inhibits both neutral endopeptidase and the endogenous endothelin producing system is a compound corresponding to Formula I,

wherein

R¹ is hydrogen or a group forming a biolabile carboxylic acid ester,

A represents a group selected from the subgroups:

(a),

wherein

R² is hydrogen or a a group forming a biolabile carboxylic acid ester, and ^R3 is a phenyl-C_1-4-alkyl group which can optionally be substituted in the phenyl ring by C_1-4-alkyl, C_1-4-alkoxy or halogen;

or a naphthyl-C_1-4-alkyl group;

(b),

wherein

R⁴ is hydrogen or a group forming a biolabile phosphonic acid ester, and

R⁵ is hydrogen or a group forming a biolabile phosphonic acid ester; and

(c),

wherein

R⁶ is hydrogen or a group forming a biolabile carboxylic acid ester,

R⁷ is hydrogen, C_1-4-alkyl or C_1-4-hydroxyalkyl, the hydroxyl group of which is optionally esterified with C_2-4-alkanoyl or an amino acid residue, and

R⁸ is C_1-4-alkyl;

C_1-4-alkoxy-C_1-4-alkyl;

C_1-4-hydroxyalkyl, which is optionally substituted by a second hydroxyl group, and the hydroxyl groups of which are each optionally esterified with C_2-4-alkanoyl or an amino acid residue;

(C_0-4-alkyl)₂amino-C_1-6-alkyl;

C_3-7-cycloalkyl;

C_3-7-cycloalkyl-C_1-4-alkyl;

phenyl-C_1-4-alkyl, the phenyl group of which is optionally substituted 1-2 times by C_1-4-alkyl, C_1-4-alkoxy and/or halogen;

naphthyl-C_1-4-alkyl;

C_3-6-oxoalkyl;

phenylcarbonylmethyl, the phenyl group of which is optionally substituted one or two times by C_1-4-alkyl, C_1-4-alkoxy and/or halogen, or 2-oxoazepanyl, or

R⁷ and R⁸ together are C_4-7-alkylene, the methylene groups of which are optionally replaced one or two times by carbonyl, nitrogen, oxygen and/or sulfur and which are optionally substituted once by hydroxy, which is optionally esterified with C_2-4-alkanoyl or an amino acid residue;

C_1-4-alkyl;

C_1-4-hydroxyalkyl, the hydroxyl group of which is optionally esterified with C_2-4-alkanoyl or an amino acid residue;

phenyl or benzyl;

or a physiologically compatible salt thereof.

10. A pharmaceutical composition according to claim 9, wherein said dually acting compound which inhibits both neutral endopeptidase and the endogenous endothelin producing system is a compound corresponding to Formula Ia,

wherein

R¹ is hydrogen or a group forming a biolabile carboxylic acid ester,

R² is hydrogen or a a group forming a biolabile carboxylic acid ester, and

R³ is a phenyl-C_1-4-alkyl group which can optionally be substituted in the phenyl ring by C_1-4-alkyl, C_1-4-alkoxy or halogen;

or a naphthyl-C_1-4-alkyl group;

or a physiologically compatible salt thereof.

11. A pharmaceutical composition according to claim 10, wherein said dually acting compound which inhibits both neutral endopeptidase and the endogenous endothelin producing system is selected from the group consisting of:

2-[1-(1-Carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylcarbamoyl)-cyclopentylmethyl]-4-phenyl-butyric acid ethyl ester;

2-[1-(1-Carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylcarbamoyl)-cyclopentylmethyl]-4-naphthalen-1-yl-butyric acid ethyl ester;

2-[1-(1-Carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylcarbamoyl)-cyclopentylmethyl]-4-phenyl-butyric acid;

2-[1-(1-carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylcarbamoyl)-cyclopentylmethyl]-4-naphthalen-1-yl-butyric acid;

and physiologically compatible salts thereof.

12. A pharmaceutical composition according to claim 9, wherein said dually acting compound which inhibits both neutral endopeptidase and the endogenous endothelin producing system is a compound corresponding to Formula Ic,

wherein

R⁶ is is hydrogen or a group forming a biolabile ester,

R⁷ is hydrogen, C_1-4-alkyl or C_1-4-hydroxyalkyl, the hydroxyl group of which is optionally esterified with C2-4-alkanoyl or an amino acid residue, and

R⁸ is C_1-4-alkyl;

C_1-4-alkoxy-C_1-4-alkyl;

C_1-4-hydroxyalkyl, which is optionally substituted by a second hydroxyl group and the hydroxyl groups of which are each optionally esterified with C₂₄-alkanoyl or an amino acid residue;

(C_0-4-alkyl)₂amino-C_1-6-alkyl;

C_3-7-cycloalkyl;

C_3-7-cycloalkyl-C_1-4-alkyl;

phenyl-C_1-4-alkyl, the phenyl group of which is optionally substituted 1-2 times by C_1-4-alkyl, C_1-4-alkoxy and/or halogen;

naphthyl-C_1-4-alkyl;

C_3-6-oxoalkyl;

phenylcarbonylmethyl, the phenyl group of which is optionally substituted 1-2 times by C_1-4-alkyl, C_1-4-alkoxy and/or halogen, or 2-oxoazepanyl, or

R⁷ and R⁸ together are C_4-7-alkylene, the methylene groups of which are optionally replaced 1-2 times by carbonyl, nitrogen, oxygen and/or sulfur and which are optionally substituted once by hydroxy, which is optionally esterified with C_2-4-alkanoyl or an amino acid residue;

C_1-4-alkyl;

C_1-4-hydroxyalkyl, the hydroxyl group of which is optionally esterified with C_2-4-alkanoyl or an amino acid residue;

phenyl or benzyl;

or a physiologically compatible salt thereof.

13. A pharmaceutical composition according to claim 12, wherein R⁷ denotes hydrogen, methyl, ethyl, 2-hydroxyethyl or 3-hydroxypropyl, each hydroxyl group optionally being esterified with C_2-4-alkanoyl or an amino acid residue.

14. A pharmaceutical composition according to claim 12, wherein R⁸ denotes isopropyl;

methoxyethyl;

2-hydroxyethyl or 3-hydroxypropyl, each hydroxyl group optionally being esterified with C_2-4-alkanoyl or an amino acid residue;

3-acetyloxy-n-propyl;

cyclopropylmethyl;

2-methoxybenzyl, 4-methoxybenzyl;

4-methoxyphenylethyl;

2,4-dimethoxybenzyl;

1-naphthylmethyl;

3-oxo-1,1-dimethylbutyl;

phenyl-2-oxoethyl;

2-(4-methoxyphenyl)-2-oxoethyl;

3-(2-oxoaze-panyl);

(C_0-4-alkyl)₂amino-C_1-6-alkyl.

15. A pharmaceutical composition according to claim 12, wherein R⁸ denotes dimethylamino-n-propyl, (methyl)aminoethyl, amino-n-propyl, amino-n-butyl, or amino-n-pentyl.

16. A pharmaceutical composition according to claim 1, wherein said at least one PDE V inhibitor is selected from the group consisting of avanafil, AWD-12-250, BF/GP-385, BMS-22313, BMS-341400 , CP-248, CP-461, DA-8159, dasantafil, DMPPO, E-4021, E-8010, EMD-82639, EMR-62203, exisulind, FR-181074, FR-226807, FR-229934, GF-248, KF-31327, KT-734, LAS-34179, lusupultide, MJ-12504, NCX-911, NM-702, OPC-35564, OSI-461, QAD-171A, roflumilast, SB-96231, Sch-46642, Sch-51866, Sch-59498, sildenafil, sildenafil citrate, SK-350, SK-3530, SKF-96231, sophoflavescenol, SR-265579, T-0156, T-1032, tadalafil, UK-1 14502, UK-1 14542, UK-357903, UK-369003, UK-371800, UK-83405, vardenafil, WIN-65579, WS-63967, YC-1, zaprinast, and physiologically compatible salts, solvates, prodrugs and esters thereof.

17. A pharmaceutical composition according to claim 1, wherein said at least one PDE V inhibitor is selected from the group consisting of avanafil, dasantafil, sildenafil, sildenafil citrate, tadalafil, vardenafil, zaprinast, and physiologically compatible salts, solvates, prodrugs and esters thereof.

18. A pharmaceutical composition according to claim 1, wherein said at least one PDE V inhibitor is selected from the group consisting of sildenafil, sildenafil citrate, tadalafil, vardenafil, and physiologically compatible salts, solvates, prodrugs and esters thereof.

19. A method of treating or inhibiting an endothelial dysfunction in a human or other mammal subject in need thereof, said method comprising administering to said subject an effective amount of a combination of (a) at least one neutral endopeptidase inhibitor, (b) at least one inhibitor of the endogenous endothelin producing system, and (c) at least one PDE V inhibitor.

20. A method of treating or inhibiting a sexual dysfunction in a human or other mammal subject in need thereof, said method comprising administering to said subject an effective amount of a combination of at least one neutral endopeptidase inhibitor, at least one inhibitor of the endogenous endothelin producing system, and at least one PDE V inhibitor.

21. A method according to claim 20, wherein said sexual dysfunction is a female sexual dysfunction.

22. A method according to claim 20, wherein said sexual dysfunction is a male sexual dysfunction.

23. A method according to claim 22, wherein said male sexual dysfunction is selected from the group consisting of erectile dysfunction, ejaculatory disorders and desire disorders.

24. A method according to claim 23, wherein the sexual dysfunction is erectile dysfunction.

25. A method of treating or inhibiting a cardiovascular disease in a human or other mammal subject in need thereof, said method comprising administering to said subject an effective amount of a combination of at least one neutral endopeptidase inhibitor, at least one inhibitor of the endogenous endothelin producing system, and at least one PDE V inhibitor.

26. A method according to claim 25, wherein said cardiovascular disease is selected from the group consisting of angina pectoris, angina abdominalis, arrhythmias, cardiac hypertrophy, congestive heart failure, coronary heart disease, hypertension, myocardial infarction, restenosis, and stroke.

27. A method according to claim 25, wherein said cardiovascular disease is selected from the group consisting of essential hypertension, pulmonary hypertension, renal hypertension, and hypertension associated with obesity, insulin resistance or diabetes.

28. Method according to claim 25, wherein said cardiovascular disease is selected from the group consisting of essential hypertension, pulmonary hypertension and congestive heart failure.

29. A kit comprising in separate containers in a single package pharmaceutical dosage forms for use in combination, comprising:

i1) in one separate container a pharmaceutical dosage form comprising at least one neutral endopeptidase inhibitor and in a second separate container a pharmaceutical dosage form comprising at least one inhibitor of the endogenous endothelin producing system, or

i2) in one separate container a pharmaceutical dosage form comprising a dually acting compound capable of inhibiting neutral endopeptidase and the endogenous endothelin producing system, and

ii) in another separate container a pharmaceutical dosage form comprising at least one PDE V inhibitor.

30. A kit according to claim 29, comprising in separate containers in a single package pharmaceutical dosage forms for use in combination, comprising:

i) in one separate container a pharmaceutical dosage form comprising a dually acting compound capable of inhibiting neutral endopeptidase and the endogenous endothelin producing system, and

ii) in another separate container a pharmaceutical dosage form comprising at least one PDE V inhibitor.